All In Biotech

Drug Trial Radar · NCT07613359

A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant

A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Mezagitamab (TAK-079) in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Oct 27, 2026

Primary completion

Jan 15, 2029

Study completion Jan 15, 2029

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
May 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Antibody-mediated rejection (AMR) is a major cause of worsening kidney function after a kidney transplant (kidney allograft dysfunction) and can lead to kidney failure. AMR happens when the kidney recipient's immune system makes antibodies that attack the donor kidney. Antibodies are proteins made by the immune system to recognize foreign cells. Over time, this attack can damage kidney tissue and cause the transplant to fail. Because AMR can be serious, there is a need for treatments that are safe, work well, and are supported by good evidence. The main aim of this study is to find out how safe mezagitamab is and how well adults with AMR tolerate it compared with placebo. A placebo looks like medicine but has no active ingredients. The study will also look at whether mezagitamab helps to control inflammation in the transplanted kidney and helps keep kidney function stable, compared with placebo. Participants will be placed by chance in 1 of the 3 treatment groups in equal numbers. Two groups will receive mezagitamab in two different doses. One group will receive placebo. This means that out of every 3 participants, 2 will receive mezagitamab and 1 will receive placebo. During the study, participants will visit their study clinic several times.

Conditions

  • Antibody-Mediated Rejection (AMR)

Interventions

  • MezagitamabDrug

    Mezagitamab subcutaneous (SC) injection.

  • PlaceboDrug

    Mezagitamab-matching placebo SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arms A, B, and C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Week 70
  2. Arms A, B, and C: Number of Participants With Related TEAEsTime frame: Up to Week 70
  3. Arms A, B, and C: Number of Participants With Serious Adverse Events (SAEs)Time frame: Up to Week 70
  4. Arms A, B, and C: Number of Participants With AEs of Special InterestTime frame: Up to Week 70
  5. Arms A, B, and C: Number of Participants With AE Leading to Treatment DiscontinuationTime frame: Up to Week 70
  6. Arms A, B, and C: Number of Participants With Clinically Significant Abnormal Laboratory Test Results and Vital SignsTime frame: Up to Week 70

Locations

35 sites in 5 countries. Site status is shown where the registry gives one.

  • UCLA University of California Los Angeles

    Los Angeles, California · Not yet recruiting

  • Kaiser Permanente-San Francisco Medical Center - Kidney Transplant Clinic

    San Francisco, California · Not yet recruiting

  • University of Miami Hospital and Clinics

    Miami, Florida · Not yet recruiting

  • Tampa General Hospital

    Tampa, Florida · Not yet recruiting

  • University of Maryland

    Baltimore, Maryland · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Not yet recruiting

  • Cooperman Barnabas Medical Center

    Livingston, New Jersey · Recruiting

  • NYU Langone Health - Transplant Associates

    New York, New York · Not yet recruiting

  • Weill Cornell Medicine - Nephrology and Kidney Transplantation Medicine

    New York, New York · Not yet recruiting

  • Cleveland Clinic - Cleveland

    Cleveland, Ohio · Not yet recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Not yet recruiting

  • Intermountain Healthcare

    Murray, Utah · Not yet recruiting

  • Virginia Commonwealth University (VCU) - Medical Center - Hume-Lee Transplant Center (HLTC)

    Richmond, Virginia · Not yet recruiting

  • Froedtert and The Medical College of Wisconsin

    Milwaukee, Wisconsin · Not yet recruiting

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangdong, Guangdong, China · Not yet recruiting

  • The Second Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Not yet recruiting

  • Tongji Hospital Affiliated to Tongji Medicine University

    Wuhan, Hubei, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Not yet recruiting

  • Shandong Provincial Qianfoshan Hospital

    Jinan, Shandong, China · Not yet recruiting

  • West China Hospital Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

  • CHU Bordeaux, CHU Pellegrin

    Bordeaux, France · Not yet recruiting

  • Hopital Henri Mondor

    Créteil, France · Not yet recruiting

  • Hopital Edouard Herriot (HEH)

    Lyon, France · Not yet recruiting

  • CHU de Toulouse - Hopital Rangueil

    Toulouse, France · Not yet recruiting

  • Ludwig-Maximilians-Universitaet Muenchen (LMU) Klinikum der Universitaet Muenchen

    München, Germany · Not yet recruiting

  • Universitaetsklinikum Muenster

    Münster, Germany · Not yet recruiting

  • Kliniken Universitatsklinikum Bochum GmbH

    Bochum, North Rhine-Westphalia, Germany · Not yet recruiting

  • Universitaetsklinikum Essen

    Essen, North Rhine-Westphalia, Germany · Not yet recruiting

  • Niigata University Medical and Dental Hospital

    Niigata, Japan · Not yet recruiting

  • Osaka Metropolitan University Hospital

    Osaka, Japan · Not yet recruiting

  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital

    Nagoya, Aichi-ken, Japan · Recruiting

  • Japanese Red Cross Kumamoto Hospital

    Kumamoto, Kumamoto, Japan · Recruiting

  • Yochomachi Clinic

    Shinjuku-ku, Tokyo, Japan · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.